Search - tctmd.com

Displaying 1 - 20 of 72

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Top Structural Heart News of 2024

L.A. McKeown

December 29, 2024

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

L.A. McKeown

December 03, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Triple Therapy Polypill for High Blood Pressure

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Top Structural Heart News of 2024

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

Little Pre- and Postmarket Testing for Most Recalled CV Devices

FDA Approves Bioresorbable Scaffold for BTK Lesions

Bempedoic Acid Gains CV Risk Reduction Indication

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

FDA Grants MACE Reduction Indication for Semaglutide

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Top Endovascular News of 2023

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Grants Tirzepatide a New Indication for Obesity Management

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content